ASH 2016 Dr Rampal shares MPN updates on Clinical Research with PV Reporter

Ruxolitinib (Jakafi) plus PIM and CDK4/6 Inhibitors

First in ASH 2016 Series

by David Wallace

Dr. Raajit Rampal from Memorial Sloan Kettering Cancer Center in New York City, presented pre-clinical data from a trial of a three drug combination in animal models in MPNs.  The combination of ruxolitinib, PIM447 ( a drug that targets PIM kinases) and LEE011 (a drug that targets the cell cycle by inhibiting CDK4/6) was effective at suppressing the growth of JAK2 mutant cells in vitro and in vivo.  The treatment reduced the allele burden somewhat and prevented the development of fibrosis.  The three-drug combo is currently being evaluated in a Phase 1 study.

error: Content is protected !